#pharmanews — Public Fediverse posts

https://www.europesays.com/dk/76609/ Novo sees comeback as weight-loss pill boom revives investor confidence – Firstpost #DenmarkPharma #EliLilly #Foundayo #GLP1Drugs #HealthcareStocks #NovoNordisk #NovoShares #ObesityDrugs #ObesityTreatmentMarket #ozempic #PeptideTherapies #PharmaNews #WegovyPill #WeightLossDrugCompetition #WeightLossPill

https://www.europesays.com/dk/61985/ Novo Nordisk Partners With OpenAI To Accelerate Drug Discovery #AIIntegration #AIIntegrationInHealth #ArtificialIntelligence #ChronicAilments #ChronicDisease #DiabetesResearch #DrugDiscovery #HealthAndAI #HealthcareInnovation #NovoNordisk #NovoNordiskDiabetesTreatment #NovoNordiskObesityDrugWegovy #NovoNordiskWeightLossDrig #OpenAI #PharmaNews #PharmaceuticalManufacturers #SamAltlam #SamAltmanAI

ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

#TycoonWorld #ChildhoodBlindness #PreventableBlindness #RightToSight #EyeHealth #PaediatricOphthalmology #VisionCare #ROPPrevention #RetinopathyOfPrematurity #GlobalHealth #PublicHealth #SDG3 #HealthForAll #ChildHealth #HealthcareInnovation #PharmaNews #ENTODPharmaceuticals #Ophthalmology #EarlyScreening

https://tycoonworld.in/entod-pharmaceuticals-joins-global-efforts-to-tackle-preventable-childhood-blindness/

ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

#TycoonWorld #ChildhoodBlindness #PreventableBlindness #RightToSight #EyeHealth #PaediatricOphthalmology #VisionCare #ROPPrevention #RetinopathyOfPrematurity #GlobalHealth #PublicHealth #SDG3 #HealthForAll #ChildHealth #HealthcareInnovation #PharmaNews #ENTODPharmaceuticals #Ophthalmology #EarlyScreening

https://tycoonworld.in/entod-pharmaceuticals-joins-global-efforts-to-tackle-preventable-childhood-blindness/

ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

#TycoonWorld #ChildhoodBlindness #PreventableBlindness #RightToSight #EyeHealth #PaediatricOphthalmology #VisionCare #ROPPrevention #RetinopathyOfPrematurity #GlobalHealth #PublicHealth #SDG3 #HealthForAll #ChildHealth #HealthcareInnovation #PharmaNews #ENTODPharmaceuticals #Ophthalmology #EarlyScreening

https://tycoonworld.in/entod-pharmaceuticals-joins-global-efforts-to-tackle-preventable-childhood-blindness/

ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

#TycoonWorld #ChildhoodBlindness #PreventableBlindness #RightToSight #EyeHealth #PaediatricOphthalmology #VisionCare #ROPPrevention #RetinopathyOfPrematurity #GlobalHealth #PublicHealth #SDG3 #HealthForAll #ChildHealth #HealthcareInnovation #PharmaNews #ENTODPharmaceuticals #Ophthalmology #EarlyScreening

https://tycoonworld.in/entod-pharmaceuticals-joins-global-efforts-to-tackle-preventable-childhood-blindness/

ENTOD Pharmaceuticals Joins Global Efforts to Tackle Preventable Childhood Blindness

#TycoonWorld #ChildhoodBlindness #PreventableBlindness #RightToSight #EyeHealth #PaediatricOphthalmology #VisionCare #ROPPrevention #RetinopathyOfPrematurity #GlobalHealth #PublicHealth #SDG3 #HealthForAll #ChildHealth #HealthcareInnovation #PharmaNews #ENTODPharmaceuticals #Ophthalmology #EarlyScreening

https://tycoonworld.in/entod-pharmaceuticals-joins-global-efforts-to-tackle-preventable-childhood-blindness/

CDSCO flags 167 drug samples as Not of Standard Quality (NSQ) in December, including spurious drugs. Learn about the latest drug safety alerts and regulatory actions. https://english.mathrubhumi.com/news/india/cdsco-drug-quality-alert-december-h3iajdl6?utm_source=dlvr.it&utm_medium=mastodon #CDSCO #DrugSafety #NSQDrugs #MedicineQuality #PharmaNews

New lawsuits claim Ozempic and other GLP-1 drugs may be linked to NAION-related vision loss. Patients allege unexpected blindness risks. Read More Here: https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/
#Ozempic #GLP1 #NAION #VisionLoss #DrugSafety #PharmaNews

https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/

New lawsuits claim Ozempic and other GLP-1 drugs may be linked to NAION-related vision loss. Patients allege unexpected blindness risks. Read More Here: https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/
#Ozempic #GLP1 #NAION #VisionLoss #DrugSafety #PharmaNews

https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/

New lawsuits claim Ozempic and other GLP-1 drugs may be linked to NAION-related vision loss. Patients allege unexpected blindness risks. Read More Here: https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/
#Ozempic #GLP1 #NAION #VisionLoss #DrugSafety #PharmaNews

https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/

New lawsuits claim Ozempic and other GLP-1 drugs may be linked to NAION-related vision loss. Patients allege unexpected blindness risks. Read More Here: https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/
#Ozempic #GLP1 #NAION #VisionLoss #DrugSafety #PharmaNews

https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/

New lawsuits claim Ozempic and other GLP-1 drugs may be linked to NAION-related vision loss. Patients allege unexpected blindness risks. Read More Here: https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/
#Ozempic #GLP1 #NAION #VisionLoss #DrugSafety #PharmaNews

https://www.jdsupra.com/legalnews/ozempic-blindness-lawsuits-legal-claims-1081107/

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Merck claims late-stage study success for RSV antibody  — Novo Nordisk's Wegovy gets UK approval for lowering heart risks — J&J vets burst into biotech with $165M Third Arc series A —http://bit.ly/w28kSd #rsv #merck #novonordisk #uk #wegovy #funding #jnj #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Abbott plans marketing push for glucose monitors beyond diabetes  — Morphic kept it simple in M&A maneuvers, staying focused on Lilly to reel in $3.2B buyout— FDA launches innovation hub to spur rare disease R&D —http://bit.ly/w28kSd #cgms #glucosemonitoring #abbottlabs #elililly #innovation #fda #rarediseases #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Despite layoff announcements, Novartis beats Q2 expectations   — GoodRx teams with Boehringer on Humira biosimilar— Medtech firms have cut more than 14,000 jobs in the past 18 months —http://bit.ly/w28kSd #novartis #earnings #layoffs #humira #biosimilar #goodrx #abbvie #medtech #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Despite layoff announcements, Novartis beats Q2 expectations   — GoodRx teams with Boehringer on Humira biosimilar— Medtech firms have cut more than 14,000 jobs in the past 18 months —http://bit.ly/w28kSd #novartis #earnings #layoffs #humira #biosimilar #goodrx #abbvie #medtech #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Despite layoff announcements, Novartis beats Q2 expectations   — GoodRx teams with Boehringer on Humira biosimilar— Medtech firms have cut more than 14,000 jobs in the past 18 months —http://bit.ly/w28kSd #novartis #earnings #layoffs #humira #biosimilar #goodrx #abbvie #medtech #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 neuro data readouts to watch in the second half of 2024 — GSK moves to new HQ in return to central London — AbbVie led the way in paying doctors to pitch its drugs last year —http://bit.ly/w28kSd #clinicaltrials #neurology #gsk #london #abbvie #physicians #physicianpayments #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Pfizer moves forward with once-daily version of weight loss pill after setbacks—Novo’s once-weekly insulin rejected by FDA — Could pharma’s blockbuster immunotherapies work in dogs? —http://bit.ly/w28kSd #pfizer #weightloss #novonordisk #type1diabetes #fda #insulin #animalhealth #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

2024's layoff woes continue in Q2—Jaguar Gene’s JAG201 therapy trial for autism receives FDA approval — Most patients stop using Wegovy, Ozempic for weight loss within two years —http://bit.ly/w28kSd #layoffs #genetherapy #autism #wegovy #ozempic #weightloss #novonordisk #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

US government appeals Gilead's trial win in Truvada, Descovy patent fight—Lilly’s Mounjaro helps patients lose more weight than Novo’s Ozempic — FTC report finds PBM power has “dire consequences” —http://bit.ly/w28kSd #gileadsciences #patents #elililly #mounjaro #ozempic #novonordisk #ftc #pbms #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —http://bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —http://bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —http://bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Lilly inks $3.2B Morphic buyout to snag oral rival to Takeda's IBD blockbuster—GLP-1s may cut risk of 10 obesity-related cancers in diabetics —Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births —http://bit.ly/w28kSd #mergersandacquistions #elililly #ibd #takeda #glp1 #novonordisk #diabetes #cancer #pfizer #rsv #vaccines #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna receives $176 million from BARDA for mRNA influenza vaccines—J&J, Legend's Carvykti shows CAR-T can extend lives in multiple myeloma —The IRA will lower U.S. drug spending, CMS finds — but not for awhile—http://bit.ly/w28kSd #moderna #barda #mrna #vaccines #flu #jnj #multiplemyeloma #ira #drugspending #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Gilead’s Trodelvy stumbles in late-stage trials but remains prized cancer asset—BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival —Supreme Court’s Chevron Doctrine ruling could limit FDA’s regulatory authority—http://bit.ly/w28kSd #gileadsciences #cancer #antibodydrugconjufate #eisai #bristolmyerssquibb #supremecourt #fda #chevrondoctrine #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

​​​​​​​Alumis cuts IPO size, but nets $250M for immune drug work—Philips BiPAP recall now linked to 65 deaths, 952 injuries —Where the future of Alzheimer's drugs is heading—http://bit.ly/w28kSd #ipos #recalls #medtech #bipap #philips #alzheimers #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Supreme Court rejects controversial Purdue Pharma bankruptcy deal—FDA approves Verona Pharma's inhaled COPD therapy —FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug—http://bit.ly/w28kSd #supremecourt #purduepharma #bankruptcy #opioidcrisis #fda #copd #merck #cancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

After full approval, Sarepta lays out its next moves—Zealand Pharma brings in $1B to drive development of obesity drugs —Sanofi seeks initial offers for Its $20 billion consumer arm—http://bit.ly/w28kSd #sareptatherapeutics #dmd #obesity #zealandpharma #funding #consumerhealth #sanofi #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

5 FDA decisions to watch in the second half of 2024—Lilly sees path for Zepbound’s label expansion with phase III sleep apnea win —BMS gets FDA approval for Krazati in colorectal cancer—http://bit.ly/w28kSd #fda #elililly #sleepapnea #bristolmyerssquibb #colorectalcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Chronic kidney disease market estimated to grow at 19.6%, driven by pipeline agents aimed at unmet needs—Lexicon Pharmaceuticals resubmits sotagliflozin NDA for type 1 diabetes —Former Stimwave CEO gets 6 years in prison for fake device scheme—http://bit.ly/w28kSd #chronickidneydisease #kidneydisease #medtech #type1diabetes #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Biopharma dealmaking continues to rise, but M&A values hold steady—Vanda rejects buyout offers, pans 'opportunistic attempts' at securing its shares at a discount —Lilly files more lawsuits to curb sales of counterfeit Mounjaro—http://bit.ly/w28kSd #mergersandacquisitions #vandapharma #elililly #counterfeitdrugs #mounjaro #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AstraZeneca’s Truqap flops in phase III triple-negative breast cancer trial—Merck's Keytruda snags 40th US indication, leaps ahead of GSK with broad endometrial cancer approval —Roche partners with RNA editing biotech Ascidian—http://bit.ly/w28kSd #astrazeneca #breastcancer #clinicaltrials #endometrialcancer #merck #fda #rna #roche #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

GLP-1 global obesity market to reach $111B by 2033, despite headwinds—Takeda circles leukemia rival to Novartis' Scemblix in up to $1.3B deal with Ascentage —J.P. Morgan's private financing arm closes inaugural $500M-plus biotech fund—http://bit.ly/w28kSd #obesity #glp1 #novonordisk #elililly #novartis #takeda #vml #funding #jpmorgan #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Coherus, Junshi’s PD-1 blocker Loqtorzi aces phase III liver cancer trial—Supreme Court preserves access to abortion pill mifepristone —Pfizer gene therapy for Duchenne fails to meet goals of key trial—http://bit.ly/w28kSd #surpremecourt #livercancer #pfizer #dmd #genetherapy #abortionpill #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

The 6 largest biopharma layoffs of 2024 so far—Biosecure Act left out of Department of Defense spending bill by House Rules Committee —Pfizer, Flagship name first target for multibillion-dollar collaboration: obesity—http://bit.ly/w28kSd #layoffs #biosecureact #legislation #pfizer #obesity #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

After M&A stretch, Pfizer CEO says company needs 'breathing period' from large deals—Behind Big Pharma’s layoffs — is there an end in sight? — Lilly Alzheimer’s drug gets unanimous backing of FDA panel—http://bit.ly/w28kSd #pfizer #bigpharma #layoffs #alzheimers #elililly #fda #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

Moderna’s COVID-Flu combo shot beats separate vaccines in phase III study—FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date — Boehringer, Lilly face off in MASH at EASL—http://bit.ly/w28kSd #moderna #vaccines #flu #covid19 #alzheimers #fda #eisai #biogen #elililly #mash #easl #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

AbbVie's tight grip on Humira market raises concerns about biosimilars—As biotech recovers, venture firms’ preferences appear to shift — Boehringer, Zealand heat up MASH race with strong phase II data—http://bit.ly/w28kSd #abbvie #humira #biosimilars #funding #mash #nash #boehringeringelheim #ipos #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma